ClinicalTrials.gg
RecruitingNCT03945162Updated Nov 24, 2025

Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients

A Phase 2 interventional study of Ruvidar® (TLD-1433) bladder infusion and PDT in Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG, sponsored by Theralase® Technologies Inc.. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Theralase® Technologies Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
38th of 93
90 · median 55
Started
2019
with 9 others
Phase 2
20 of 114
8 open now
Primary completion
2026-12
later than 13 of 59 live
Registered
40th of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 38th largest by planned enrollment of the 93 interventional ones that give a count, is one of 10 that started in 2019, is one of 20 in phase 2, reaches primary completion later than 13 of the 59 other live ones, and was the 40th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary disease (Ta, T1)) that are considered Bacillus Calmette-Guerin ("BCG")-Unresponsive or who are intolerant to BCG therapy. BCG-Unresponsive is at least one of the following: At least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy; or, at least five of six doses of an initial induction course plus at least two of six doses of a second induction course. Patients experiencing disease relapse within 12 months after finishing the second course of BCG therapy are considered BCG-Unresponsive. The Study will consist of 90 patients who will undergo one (1) Study Procedure, with up to two (2) additional re-induction Study Procedures based on patient response.

Read the detailed description
  1. Overall Study Design and Plan: Description

    This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with NMIBC CIS (with or without resected papillary disease (Ta, T1)) that are considered BCG-Unresponsive or are intolerant to BCG therapy that meet the inclusion and exclusion criteria will be enrolled and treated. The Study will consist of 90 patients who will receive one (1) Study Procedure, with up to two (2) additional re-induction Study Procedures based on patient response.

  2. Screening Period

    Patients will be qualified for Study II entry by review of inclusion and exclusion criteria during the Screening Period, which will last up to 60 days.

  3. Follow-Up Phase

    All patients enrolled and treated by the treatment procedure will be followed until the End of Study defined as completion of all required assessments after 15 months of follow-up post primary study treatment or due to early discontinuation or withdrawal of informed consent.

    During the Follow-Up Phase, information on efficacy and safety will be collected. Assessments will be conducted at Day 0, 7, 90, 180, 270, 360 and 450 days.

    Survival surveillance for all patients who achieve a CR or Indeterminate Response ("IR") (negative cystoscopy and positive urine cytology, without confirmatory negative bladder cancer biopsies) at four hundred and fifty (450) days and remain in Study II will be monitored for up to one thousand and eighty (1080) days post primary Study II Treatment, recording: efficacy, safety and incidence of radical cystectomy every ninety (90) days for the first seven hundred and twenty (720) days, then every one hundred and eighty (180) days, until one thousand and eighty (1080) days.

  4. Study Drug and PDT Administration

Ruvidar® (TLD-1433) for intravesical administration is supplied as a lyophilisate for suspension in Sterile Water For Injection ("SWFI") into the bladder and is packaged in the dark in amber USP Type III glass vials, which are stored at 3 to 8 degree Celsius. Up to 24 hours before administration, it is reconstituted with SWFI to obtain the final clinical dilution.

Ruvidar® (TLD-1433) will be supplied to each Study II site by Theralase®. Instillations cannot be done immediately following biopsy taken by Trans-Urethral Resection of Bladder Tumour ("TURBT"). Investigators must wait a minimum of 7 days before dosing patients after a TURBT/biopsy, and/or until any bladder wall integrity issues have resolved. Dose/volume reductions are not allowed during Study II.

Upon determination of the bladder volume (during the screening period) through a self-recorded voiding diary, Ruvidar® (TLD-1433) will be diluted with SWFI to the proper concentration. On day 0 (Primary Study Procedure day), patients will be asked to restrict fluid intake 12 hours before Study Drug instillation. Study Drug must be instilled into the patient's empty bladder. Before instillation, a regular transurethral catheter should be inserted and the bladder drained. A single instillation of Ruvidar® (TLD-1433) will be infused intravesically for approximately 60 minutes, followed by 1 wash with SWFI. The bladder will be distended using a second instillation of SWFI to prevent folds that may prevent uniform light illumination. The Computer Operator worksheet must be completed during the Study Procedure and data must be promptly transferred to the corresponding electronic Case Report Form ("eCRF") page.

The optical fiber with spherical diffuser will be positioned through the cystoscope in the geometric center of the bladder with the aid of TLC-3200 and will be locked into place using an endoscope holder for continuous irradiation for the total exposure time. The optical power and treatment time will be determined to provide the correct dose of laser light to the bladder surface area. Green laser light (wavelength = 532 nm, energy = 90 J/cm2) will be irradiated from the emitter optical fiber via the spherical diffuser.

4.1 Dosing Schedule

One Study Procedure is planned, with up to two additional re-induction Study Procedures based on patient response. Each Study Procedure is a single whole bladder intravesical Ruvidar® (TLD-1433) instillation followed by PDT with the TLC-3200 System.

4.2 PDT Disruption

Patients with persistent or recurrent NMIBC CIS alone (or with recurrent Ta/T1 (noninvasive papillary disease/tumour invades the subepithelial connective tissue)) disease within 12 months of completion of BCG therapy (BCG-Unresponsive) or who are intolerant to BCG therapy will be treated with this Protocol. If one or more papillary tumours are seen at the time of Study Treatment (maximum 12 weeks after TURBT), the patient will be resected via TURBT and will be treated with this Protocol.

03

Conditions studied

  • Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG

Keywords

  • Photodynamic Therapy
  • Non-muscle invasive bladder cancer ("NMIBC")
  • Urothelial carcinoma
  • Ta bladder cancer
  • T1 bladder cancer
  • Unresponsive/Intolerant to BCG
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be willing and able to provide a written Form ("ICF") for the Study.
  2. Be > 18 years of age on day of signing ICF.
  3. Have confirmed NMIBC CIS via with/without resected papillary disease (Ta, T1) (high grade) using the 2004 World Health Organization ("WHO") / International Society of Urologic Pathology classification system. The most recent cystoscopy / TURBT must have been performed within 12 weeks of the Study Procedure date to confirm: histology, grade and stage.
  4. Intolerant to BCG or considered BCG-Unresponsive, which is at least one of the following:

    • At least five of six doses of an initial induction course, plus at least two of three doses of maintenance therapy, or
    • At least five of six doses of an initial induction course, plus at least two of six doses of a second induction course.
  5. Are not candidates for cystectomy on medical grounds or refuse radical cystectomy.
  6. Have an ("ECOG") performance score of 0 to 2.
  7. Have satisfactory bladder function. Ability to retain Study Drug for a minimum of 60 minutes.
  8. Are available for the duration of the Study including follow-up (approximately 15 months).
  9. Female patients of must have a negative Human Chorionic Gonadotropin ("HCG") pregnancy test taken during the screening visit and confirmed prior to the Study Procedure.
  10. Female patients of childbearing potential must be willing to use 2 methods of (i.e.: oral contraceptive, pills, diaphragm or condoms) or be surgically sterile, or abstain from heterosexual activity for two weeks after the Study Procedure. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for >1 year.

Exclusion criteria

Exclusion Criteria:

  1. Past or current muscle invasive (i.e.: T2, T3, T4) or urothelial carcinoma.
  2. Has concurrent extravesical (i.e.: urethra, ureter, renal pelvis, prostate or prostatic ducts) non-muscle invasive transitional cell carcinoma of the urothelium. (confirmed by staging to exclude extravesical disease, which may include radiological imaging and/or ) within 3 months of enrollment:

    If previous work up occurred more than 3 months prior to enrollment, staging for extravesical disease must be repeated prior to enrolment in order to determine eligibility.

  3. Active gross hematuria.
  4. Have a known additional that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer or localized prostate cancer under active surveillance with Gleason 6 disease. A history of prostate cancer that was treated with definitive intent (surgically or through radiation therapy) is acceptable, provided that the following criteria are met: Stage T2N0M0 or lower Prostate-Specific Antigen ("PSA") undetectable for 2 years while off androgen deprivation therapy or no more than 2 consecutive rising PSAs.
  5. Have a history or current evidence of any condition, therapy, surgery or laboratory abnormality that, in the opinion of the PI, might confound the results of the study, interfere with the patient's participation in the study, or is not in the best interest of the patient to participate.
  6. Currently receiving treatment with a prohibited concomitant therapy (refer to 12.2.1, Prohibited Medications).
  7. Participated in a study with an agent or device within 1 month from the first dose of current Study Procedure.
  8. Prior treatment with an intravesical chemotherapeutic agent within 1 month of the first dose of current Study Drug, with the exception of a single perioperative dose of chemotherapy immediately post-TURBT (not considered treatment).
  9. Have an active infection requiring systemic therapy, including active or intractable Urinary Tract Infection ("UTI"), not resolved prior to the procedure.
  10. Has any to general or spinal anesthesia.
  11. Is pregnant or breastfeeding within the projected duration of Study II, starting with the screening visit through to two weeks following the last Study Procedure.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    0.70 mg/cm^2 Ruvidar® (TLD-1433) Bladder instillation and Photodynamic Therapy

    Each Study Procedure is a single instillation of Ruvidar® (TLD-1433) (at the therapeutic dose of 0.70 mg/cm\^2) will be infused intravesically into the bladder for approximately 60 minutes, followed by PDT treatment using the TLC-3200 system, which is performed after Ruvidar® (TLD-1433) has been rinsed from the bladder. One Study Procedure will be performed, with up to 2 additional re-induction Study Procedures based on patient response.

    Combination Product: Ruvidar® (TLD-1433) bladder infusion and PDT

Interventions

  • Combination productRuvidar® (TLD-1433) bladder infusion and PDT

    Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with PDT light activation using the TLC-3200 system.

06

What researchers measure

Primary outcomes

  1. Efficacy, evaluated by Complete Response ("CR").

    The primary endpoint of Study II is efficacy, evaluated by the Complete Response ("CR") at any time point in patients with Carcinoma In-Situ ("CIS") with resected papillary disease. Patient CR is defined as at least one of the following: * Negative cystoscopy and negative (including atypical) urine cytology * Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology * Negative cystoscopy with malignant urine cytology, if urothelial cancer is suspected in the upper tract or prostatic urethra and random bladder biopsies are negative.

    Time frame: Throughout Study II and up to the completion of the follow-up phase (15 month)

Secondary outcomes

  1. Efficacy, evaluated by the duration of CR

    Assessment of the Duration the CR is maintained after an initial CR is achieved.

    Time frame: Throughout Study II and up to the completion of the follow-up phase (15 month)

  2. Three year patient assessments, for observation only.

    Survival surveillance for all patients who achieve a CR or Indeterminate Response ("IR") (negative cystoscopy and positive urine cytology, without confirmatory negative bladder cancer biopsies) at four hundred and fifty (450) days and remain in Study II will be monitored for up to one thousand and eighty (1080) days post primary Study Procedure, recording: efficacy, safety and incidence of radical cystectomy every ninety (90) days for the first seven hundred and twenty (720) days, then every one hundred and eighty (180) days, until one thousand and eighty (1080) days.

    Time frame: Follow-up phase from 15 to 36 months for those who remain in Study.

Other outcomes

  1. Safety, evaluated by the incidence and severity of Adverse Events.

    The tertiary endpoint of Study II is safety, evaluated by the incidence and severity of Adverse Events ("AEs"), Grade 4 or higher that do not resolve within 450 days post initial treatment; whereby: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening or disabling, Grade 5 = Death

    Time frame: Throughout the study and up to the completion of the follow-up phase (15 month)

07

Study locations

13 of 16 sites recruiting
  • Site 02-012 - University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • Site 02-016 - Urology of Indiana
    Greenwood, Indiana 46143, United States
    Recruiting
    • Brittiny Currin · Contactbcurrin@urologyin.com · 631-838-6670
    • Dr. Eugene Cone · Principal investigator
  • Site 02-015 - Associated Medical Professionals of New York
    Syracuse, New York 13210, United States
    Recruiting
    • Nora Hoodmaker · ContactNHoodmaker@ampofny.com · 315-558-6619
    • Dr. Ilija Aleksic · Principal investigator
  • Site 02-017 - Central Ohio Urology Group
    Gahanna, Ohio 43230, United States
    Recruiting
  • Site 02-008 - MidLantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
    Terminated

    Not enrolling at this site.

  • Site 02-006 - Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
    Recruiting
  • Site 02-007 - Urology Associates, P. C
    Nashville, Tennessee 37209, United States
    Recruiting
    • Tiffany Paine · Contacttmpaine@ua-pc.com · 615-250-9282
    • Dr. Gautam Jayram · Principal investigator
  • Site 02-010 - Urology San Antonio P. A
    San Antonio, Texas 78229, United States
    Terminated

    Not enrolling at this site.

  • Site 02-009 - Virginia Urology
    Richmond, Virginia 23235, United States
    Terminated

    Not enrolling at this site.

  • Site 02-011 - University of Wisconsin Health University Hospital
    Madison, Wisconsin 53792, United States
    Recruiting
  • Site 01-005 - The Vancouver Prostate Centre - Diamond Health Care Centre - Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
    Recruiting
  • Site 01-004 - Nova Scotia Health Authority - Centre for Applied Urology Research
    Halifax, Nova Scotia B3H 2Y9, Canada
    Recruiting
  • Site 01-014 - St. Joseph's Healthcare
    Hamilton, Ontario L8N 4A6, Canada
    Recruiting
  • Site 01-002- London Health Sciences Centre - Victoria Hospital
    London, Ontario N6A 5W9, Canada
    Recruiting
  • Site 01-001 - University Health Network - Princess Margaret Cancer Centre
    Toronto, Ontario M5G 2C4, Canada
    Recruiting
    • Sarah Cheung · Contactsarah.cheung@uhn.ca · 437-335-2949
    • Girish Kulkarni, MD · Principal investigator
  • Site 01-003 - McGill University Health Centre - Glen-Cedars Cancer Centre
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Dec 2026, 88 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2019
First posted
May 10, 2019
StartActual
Aug 30, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03945162
Lead sponsor
Theralase® Technologies Inc.
Responsible party
Sponsor
First posted
May 10, 2019
Start date
Aug 30, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 24, 2025

Study contacts

Arkady Mandel, MD, PhD, DSc
Contact
amandel@theralase.com
416-699-5273 ext. 242
Girish Kulkarni, MD, FRCSC
principal investigator · University Health Network, Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion